SCHEMBL2264845

SCHEMBL2264845

CC(=O)Cc1ccc(C(=O)ON2C(=O)CCC2=O)cn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MGLL Q99685 1/20 0.32
CRBN Q96SW2 3/20 0.32
KMT2A Q03164 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
DDB1 Q16531 1/20 0.31
HRH3 Q9Y5N1 2/20 0.31
CHRNB2 P17787 1/20 0.31
CHRNA7 P36544 1/20 0.31
CHRNA4 P43681 1/20 0.31
MEN1 O00255 1/20 0.31
P2RY12 Q9H244 1/20 0.31
SPR P35270 1/20 0.31
KCNJ1 P48048 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20278536 0.79 POLB (0.41) MAPK1ALDH1A1HPGDMGLLKMT2A
SCHEMBL4758814 0.79 HDAC1 (0.45) MAPK1L3MBTL1ALDH1A1KDM4EKMT2A
SCHEMBL12488583 0.77 MAPK1 (0.67) MAPK1L3MBTL1ALDH1A1HPGDKDM4E
Acetone SCHEMBL1019109 0.76 MAPK1 (0.40) MAPK1L3MBTL1KDM4EMGLLCRBN
SCHEMBL16938414 0.76 GABRP (0.49) MAPK1L3MBTL1ALDH1A1HPGDKDM4E
SCHEMBL27076571 0.76 MAPK1 (0.38) MAPK1L3MBTL1KDM4EMGLLKMT2A
SCHEMBL4739165 0.76 MAPK1 (0.39) MAPK1L3MBTL1ALDH1A1HPGDKDM4E
Acetone SCHEMBL17732269 0.75 MAPK1 (0.39) MAPK1L3MBTL1KDM4EMGLLCRBN
SCHEMBL1509187 0.75 MAPK1 (0.41) MAPK1L3MBTL1KDM4EMGLLCRBN
SCHEMBL9446767 0.75 CA12 (0.49) L3MBTL1ALDH1A1HPGDKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE46171-E1 Functional biopolymer modification reagents and uses thereof SOLULINK, INCORPORATED (US) 2016-10-04 US disclosed
US-7999098-B2 Triphosphate oligonucleotide modification reagents and uses thereof SOLULINK BIOSCIENCES, INC. (US) 2011-08-16 US disclosed
US-7732628-B2 Such as 4-[8-(2-cyanoethyl-N,N-diisopropylphosphoramidyloxy)-2-aza-1-oxooct-1-yl]benzaldehyde, 4-[8-(2-cyanoethyl-N,N-diisopropylphosphoramidyloxy)-2-aza-1-oxooct-1-yl]acetophenone; for incorporation into oligonucleotides during immobilization and conjugation of biopolymers in solid phase synthesis SOLULINK INCORPORATED (US) 2010-06-08 US disclosed
US-20070179288-A1 Triphosphate oligonucleotide modification reagents and uses thereof AUDAX PRIVATE DEBT LLC, AS AGENT 2007-08-02 US disclosed
US-7173125-B2 Triphosphate oligonucleotide modification reagents and uses thereof AUDAX PRIVATE DEBT LLC, AS AGENT 2007-02-06 US disclosed
US-7102024-B1 Functional biopolymer modification reagents and uses thereof AUDAX PRIVATE DEBT LLC, AS AGENT 2006-09-05 US disclosed
US-20050203289-A1 Functional biopolymer modification reagents and uses thereof AUDAX PRIVATE DEBT LLC, AS AGENT 2005-09-15 US disclosed
US-20040214199-A1 Triphosphate oligonucleotide modification reagents and uses thereof AUDAX PRIVATE DEBT LLC, AS AGENT 2004-10-28 US disclosed
US-6686461-B1 HYDRAZINO, OXYAMINO AND CARBONYL-BASED MONOMERS AND METHODS FOR LABELLING OF OLIGONUCLEOTIDES WITHOUT THE NEED FOR POST-SYNTHETIC MODIFICATION SOLULINK BIOSCIENCE, INC. 2004-02-03 US disclosed
EP-1305327-A2 TRIPHOSPHATE OLIGONUCLEOTIDE MODIFICATION REAGENTS AND USES THEREOF Schwartz, David A. (US) 2003-05-02 EP disclosed
WO-2002010432-A2 TRIPHOSPHATE OLIGONUCLEOTIDE MODIFICATION REAGENTS AND USES THEREOF SCHWARTZ DAVID A (US) 2002-02-07 WO disclosed
WO-2002010431-A2 FUNCTIONAL BIOPOLYMER MODIFICATION REAGENTS AND USES THEREOF SCHWARTZ DAVID A (US) 2002-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203289-A1 Functional biopolymer modification reagents and uses thereof OGG1, OGA, HMOX2 MAPK1 4253/4885L3MBTL1 2911/4885ALDH1A1 360/4885
US-20040214199-A1 Triphosphate oligonucleotide modification reagents and uses thereof RNGTT, DUT, NUDT1 MAPK1 3789/4885L3MBTL1 2634/4885ALDH1A1 410/4885
US-20070179288-A1 Triphosphate oligonucleotide modification reagents and uses thereof RNGTT, DUT, NUDT1 MAPK1 3897/4885L3MBTL1 2665/4885ALDH1A1 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.